JP2010537640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010537640A5 JP2010537640A5 JP2010523121A JP2010523121A JP2010537640A5 JP 2010537640 A5 JP2010537640 A5 JP 2010537640A5 JP 2010523121 A JP2010523121 A JP 2010523121A JP 2010523121 A JP2010523121 A JP 2010523121A JP 2010537640 A5 JP2010537640 A5 JP 2010537640A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- strand
- mimetic
- mirna
- overhang
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003729 nucleotide group Chemical group 0.000 description 69
- 239000003112 inhibitor Substances 0.000 description 52
- 108700011259 MicroRNAs Proteins 0.000 description 50
- 239000002679 microRNA Substances 0.000 description 50
- 239000002773 nucleotide Substances 0.000 description 48
- 238000000034 method Methods 0.000 description 39
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 32
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 17
- 125000002652 ribonucleotide group Chemical group 0.000 description 14
- 230000000295 complement effect Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000003278 mimic effect Effects 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 108091023037 Aptamer Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- 108091033773 MiR-155 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 108091023663 let-7 stem-loop Proteins 0.000 description 2
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 2
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108091062762 miR-21 stem-loop Proteins 0.000 description 2
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 2
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000005642 phosphothioate group Chemical group 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 108091053410 let-7 family Proteins 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96825707P | 2007-08-27 | 2007-08-27 | |
| US2975308P | 2008-02-19 | 2008-02-19 | |
| US3895408P | 2008-03-24 | 2008-03-24 | |
| PCT/US2008/074531 WO2009029690A1 (en) | 2007-08-27 | 2008-08-27 | Composition of asymmetric rna duplex as microrna mimetic or inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010537640A JP2010537640A (ja) | 2010-12-09 |
| JP2010537640A5 true JP2010537640A5 (enExample) | 2011-10-20 |
Family
ID=40387778
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523121A Pending JP2010537640A (ja) | 2007-08-27 | 2008-08-27 | マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物 |
| JP2010523120A Pending JP2010537639A (ja) | 2007-08-27 | 2008-08-27 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2014032700A Active JP5986596B2 (ja) | 2007-08-27 | 2014-02-24 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2015085681A Pending JP2015130885A (ja) | 2007-08-27 | 2015-04-20 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2016113256A Active JP6236498B2 (ja) | 2007-08-27 | 2016-06-07 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2016122512A Active JP6453275B2 (ja) | 2007-08-27 | 2016-06-21 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2017091309A Pending JP2017127333A (ja) | 2007-08-27 | 2017-05-01 | 非対称性干渉ｒｎａの組成物およびその使用 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523120A Pending JP2010537639A (ja) | 2007-08-27 | 2008-08-27 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2014032700A Active JP5986596B2 (ja) | 2007-08-27 | 2014-02-24 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2015085681A Pending JP2015130885A (ja) | 2007-08-27 | 2015-04-20 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2016113256A Active JP6236498B2 (ja) | 2007-08-27 | 2016-06-07 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2016122512A Active JP6453275B2 (ja) | 2007-08-27 | 2016-06-21 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2017091309A Pending JP2017127333A (ja) | 2007-08-27 | 2017-05-01 | 非対称性干渉ｒｎａの組成物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US20100286378A1 (enExample) |
| EP (4) | EP3889261A1 (enExample) |
| JP (7) | JP2010537640A (enExample) |
| CN (3) | CN101842381A (enExample) |
| CA (2) | CA2735166C (enExample) |
| DK (1) | DK2193140T3 (enExample) |
| ES (2) | ES2617877T3 (enExample) |
| WO (2) | WO2009029688A2 (enExample) |
Families Citing this family (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008073578A2 (en) | 2006-12-08 | 2008-06-19 | Iowa State University Research Foundation, Inc. | Plant genes involved in nitrate uptake and metabolism |
| EP3889261A1 (en) * | 2007-08-27 | 2021-10-06 | 1Globe Health Institute LLC | Compositions of asymmetric interfering rna and uses thereof |
| US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
| KR100949791B1 (ko) * | 2007-12-18 | 2010-03-30 | 이동기 | 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도 |
| EP2342340A1 (en) | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| CN102224254A (zh) | 2008-09-23 | 2011-10-19 | 哈佛大学校长及研究员协会 | Sirt4及其用途 |
| JP2012505657A (ja) | 2008-10-15 | 2012-03-08 | ソマジェニックス インク． | 遺伝子発現の阻害のためのショートヘアピンｒｎａ |
| WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| EP2756845B1 (en) * | 2009-04-03 | 2017-03-15 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA |
| CN103555722B (zh) * | 2009-04-03 | 2016-08-31 | 戴瑟纳制药公司 | 利用不对称双链rna特异性抑制kras的方法和组合物 |
| WO2010141933A1 (en) * | 2009-06-05 | 2010-12-09 | Dicerna Pharmaceuticals, Inc. | Specific inhibition of gene expression by nucleic acid containing a dicer substrate |
| EP2454371B1 (en) | 2009-07-13 | 2021-01-20 | Somagenics, Inc. | Chemical modification of small hairpin rnas for inhibition of gene expression |
| US8796238B2 (en) | 2009-09-17 | 2014-08-05 | Sigma-Aldrich Co. Llc | Short RNA mimetics |
| US20120301463A1 (en) | 2009-09-30 | 2012-11-29 | President And Fellows Of Harvard College | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products |
| US20150025122A1 (en) | 2009-10-12 | 2015-01-22 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
| US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
| KR101237036B1 (ko) * | 2009-11-04 | 2013-02-25 | 성균관대학교산학협력단 | 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도 |
| EP2515915A4 (en) * | 2009-12-16 | 2014-07-09 | Univ Western Ontario | COMPOSITIONS AND METHODS RELATING TO MIRNA IN DIABETIC DRESSES |
| ES2641642T3 (es) | 2010-03-08 | 2017-11-10 | Monsanto Technology Llc | Moléculas de polinucleótido para regulación génica en plantas |
| EP3560503B1 (en) | 2010-03-24 | 2021-11-17 | Phio Pharmaceuticals Corp. | Rna interference in dermal and fibrotic indications |
| RU2615143C2 (ru) | 2010-03-24 | 2017-04-04 | Адвирна | Самодоставляющие PHKi соединения уменьшенного размера |
| CN103200945B (zh) | 2010-03-24 | 2016-07-06 | 雷克西制药公司 | 眼部症候中的rna干扰 |
| US8993532B2 (en) | 2010-04-23 | 2015-03-31 | Cold Spring Harbor Laboratory | Structurally designed shRNAs |
| GB201006841D0 (en) * | 2010-04-26 | 2010-06-09 | Thomsen Lars | Method, device and system for targetted cell lysis |
| DK2631291T3 (da) | 2010-10-22 | 2019-06-11 | Olix Pharmaceuticals Inc | Nukleinsyremolekyler, der inducerer rna-interferens, og anvendelser deraf |
| CN101979558B (zh) * | 2010-10-28 | 2015-09-02 | 百奥迈科生物技术有限公司 | 一种靶向乙型肝炎病毒基因的siRNA分子及其应用 |
| WO2012140234A1 (en) | 2011-04-13 | 2012-10-18 | Vib Vzw | Modulation of mirna in diseases with aberrant angiogenesis |
| WO2012149646A1 (en) * | 2011-05-05 | 2012-11-08 | Sunnybrook Research Institute | Mirna inhibitors and their uses |
| CN107115352B (zh) | 2011-08-04 | 2020-10-30 | 耶达研究及发展有限公司 | 微rna和包含微rna的组合物 |
| UA116089C2 (uk) | 2011-09-13 | 2018-02-12 | Монсанто Текнолоджи Ллс | Спосіб та композиція для боротьби з бур'янами (варіанти) |
| US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10184151B2 (en) * | 2011-10-11 | 2019-01-22 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
| US9593331B2 (en) | 2011-11-02 | 2017-03-14 | Osaka City University | Double-stranded nucleic acid molecule for gene expression control |
| WO2013138280A1 (en) * | 2012-03-12 | 2013-09-19 | Eaker Shannon | IMPROVED ENGRAFTMENT POTENTIAL OF EMBRYONIC STEM CELLS AND PLURIPOTENT STEM CELLS USING MICRO RNAs |
| KR101567576B1 (ko) | 2012-05-22 | 2015-11-10 | 올릭스 주식회사 | 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도 |
| US10240161B2 (en) | 2012-05-24 | 2019-03-26 | A.B. Seeds Ltd. | Compositions and methods for silencing gene expression |
| WO2013180038A1 (ja) | 2012-05-26 | 2013-12-05 | 株式会社ボナック | デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子 |
| ES2534210T3 (es) * | 2012-08-29 | 2015-04-20 | Chanel Parfums Beauté | Inhibidores de micro-ARN para uso para prevenir y/o atenuar el envejecimiento cutáneo |
| US9096853B2 (en) * | 2012-09-24 | 2015-08-04 | U.S. Department Of Veterans Affairs | Modified siRNA molecules incorporating 5-fluoro-2′-deoxyuridine residues to enhance cytotoxicity |
| WO2014063155A1 (en) | 2012-10-21 | 2014-04-24 | University Of Rochester | Thy1 (cd90) as a novel therapy to control adipose tissue accumulation |
| WO2014089121A2 (en) * | 2012-12-03 | 2014-06-12 | Thomas Ichim | Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases |
| AU2014215421A1 (en) * | 2013-02-05 | 2015-08-13 | 1Globe Health Institute Llc | Biodegradable and clinically-compatible nanoparticles as drug delivery carriers |
| BR112015022797A2 (pt) | 2013-03-13 | 2017-11-07 | Monsanto Technology Llc | método para controle de ervas daninhas, composição herbicida, cassete de expressão microbiano e método de produção de polinucleotídeo |
| EP2971185A4 (en) | 2013-03-13 | 2017-03-08 | Monsanto Technology LLC | Methods and compositions for weed control |
| US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
| CA2908380A1 (en) | 2013-04-09 | 2014-10-16 | Boston Biomedical, Inc. | Methods for treating cancer |
| RU2703498C2 (ru) | 2013-07-19 | 2019-10-17 | Монсанто Текнолоджи Ллс | Композиции и способы борьбы с leptinotarsa |
| HUE070313T2 (hu) | 2013-11-04 | 2025-05-28 | Greenlight Biosciences Inc | Ízeltlábú paraziták és kártevõfertõzöttség szabályozására szolgáló készítmények és eljárások |
| CN106061488B (zh) | 2013-12-02 | 2021-04-09 | 菲奥医药公司 | 癌症的免疫治疗 |
| UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
| WO2015099122A1 (ja) | 2013-12-26 | 2015-07-02 | 学校法人東京医科大学 | 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途 |
| CN106068324B (zh) | 2013-12-27 | 2020-12-29 | 株式会社博纳克 | 控制基因表达的人工匹配型miRNA及其用途 |
| AU2015206585A1 (en) | 2014-01-15 | 2016-07-21 | Monsanto Technology Llc | Methods and compositions for weed control using EPSPS polynucleotides |
| CA2936158C (en) | 2014-02-05 | 2023-06-13 | Yeda Research And Development Co. Ltd. | Use of mir-135 or precursor thereof for the treatment and diagnosis of a bipolar disease |
| TW201620525A (zh) * | 2014-03-14 | 2016-06-16 | 波士頓生醫公司 | 使ｋ－ｒａｓ靜默之非對稱干擾ｒｎａ組成物及其使用方法 |
| BR112016022711A2 (pt) | 2014-04-01 | 2017-10-31 | Monsanto Technology Llc | composições e métodos para controle de pragas de inseto |
| WO2015168108A2 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic targeting mdm2 or mycn |
| WO2015176737A1 (en) * | 2014-05-19 | 2015-11-26 | Biontech Ag | Particles comprising protamine and rna in combination with endosome destabilizing agents |
| KR101681669B1 (ko) * | 2014-05-27 | 2016-12-02 | 주식회사 제노포커스 | 유전자 침묵에 의한 목적 단백질의 과발현 방법 |
| US10988764B2 (en) * | 2014-06-23 | 2021-04-27 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via RNA interference |
| EP3161138A4 (en) | 2014-06-25 | 2017-12-06 | Monsanto Technology LLC | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
| RU2021123470A (ru) | 2014-07-29 | 2021-09-06 | Монсанто Текнолоджи Ллс | Композиции и способы борьбы с насекомыми-вредителями |
| US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| JP6637652B2 (ja) * | 2014-11-21 | 2020-01-29 | 株式会社バイオシンクタンク | 抗腫瘍剤の選択方法およびその抗腫瘍剤が含有するｓｉＲＮＡ |
| US11045488B2 (en) | 2014-12-26 | 2021-06-29 | Nitto Denko Corporation | RNA interference agents for GST-π gene modulation |
| US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| KR20170098914A (ko) | 2014-12-27 | 2017-08-30 | 가부시키가이샤 보낙 | 유전자 발현 제어를 위한 천연형 miRNA 및 그의 용도 |
| JP6942632B2 (ja) | 2015-01-22 | 2021-09-29 | モンサント テクノロジー エルエルシー | Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法 |
| CN104673796A (zh) * | 2015-02-09 | 2015-06-03 | 暨南大学 | 靶向hsv-1病毒ul18基因的小干扰rna及应用 |
| JP2018509912A (ja) * | 2015-03-16 | 2018-04-12 | ミラゲン セラピューティクス， インコーポレイテッド | 感覚の状態を処置することにおけるｍｉＲＮＡ模倣物およびその使用 |
| WO2016158809A1 (ja) | 2015-03-27 | 2016-10-06 | 株式会社ボナック | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 |
| US20160319278A1 (en) | 2015-04-03 | 2016-11-03 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| US10883103B2 (en) | 2015-06-02 | 2021-01-05 | Monsanto Technology Llc | Compositions and methods for delivery of a polynucleotide into a plant |
| TW201717935A (zh) | 2015-06-03 | 2017-06-01 | 波士頓生醫公司 | 用於治療癌症的組成物和方法 |
| EP3302030A4 (en) | 2015-06-03 | 2019-04-24 | Monsanto Technology LLC | METHOD AND COMPOSITIONS FOR INTRODUCING NUCLEIC ACIDS IN PLANTS |
| KR20190118688A (ko) | 2015-06-05 | 2019-10-18 | 미라젠 세러퓨틱스 인코포레이티드 | 피부 t 세포 림프종(ctcl) 치료용 mir-155 억제제 |
| EP3862005A1 (en) | 2015-07-06 | 2021-08-11 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (sod1) |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| GB201516685D0 (en) * | 2015-09-21 | 2015-11-04 | Varghese Oommen P And Oommen Oommen P | Nucleic acid molecules with enhanced activity |
| WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
| JP7027311B2 (ja) | 2015-11-16 | 2022-03-01 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療 |
| WO2017100127A1 (en) | 2015-12-06 | 2017-06-15 | Boston Biomedical, Inc. | ASYMMETRIC INTERFERING RNAs, AND COMPOSITIONS, USE, OR PREPARATION THEREOF |
| BR112018008344A2 (pt) | 2015-12-13 | 2018-10-30 | Nitto Denko Corp | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, método para prevenir, tratar ou melhorar uma doença, e, uso de uma composição |
| US10478503B2 (en) | 2016-01-31 | 2019-11-19 | University Of Massachusetts | Branched oligonucleotides |
| CN108779464B (zh) | 2016-02-02 | 2022-05-17 | 奥利克斯医药有限公司 | 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病 |
| JP6944942B2 (ja) | 2016-02-02 | 2021-10-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 |
| US20190192687A1 (en) * | 2016-02-12 | 2019-06-27 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Service | Rna/dna hybrid nanoparticles modified with single stranded rna toeholds and uses thereof |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| JP7049262B2 (ja) | 2016-04-11 | 2022-04-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | 結合組織成長因子を標的とするｒｎａ複合体を用いた特発性肺胞線維症の治療 |
| KR102427379B1 (ko) | 2016-05-18 | 2022-08-02 | 보이저 테라퓨틱스, 인크. | 헌팅톤 질환을 치료하기 위한 조성물 및 방법 |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| WO2018005444A2 (en) | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| CN107630015B (zh) | 2016-07-19 | 2021-03-09 | 上海市东方医院 | 一种稳定的dna-rna双链结构 |
| CA3033368A1 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
| CA3041761A1 (en) * | 2016-10-31 | 2018-05-03 | Gifu University | Double-stranded nucleic acid molecule and use thereof |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| WO2018102427A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| AU2018216509B2 (en) * | 2017-01-31 | 2024-02-29 | Curigin Co.,Ltd. | Nucleic acid simultaneously inhibiting expression of mTOR gene and STAT3 gene |
| EP3580339A4 (en) | 2017-02-10 | 2020-12-23 | Research & Business Foundation Sungkyunkwan University | LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE |
| WO2018160887A1 (en) * | 2017-03-01 | 2018-09-07 | Boston Biomedical, Inc. | Pdl1-specific and beta-catenin-specific asymmetric interfering rna compositions, uses or preparation thereof |
| US12544344B2 (en) | 2017-04-19 | 2026-02-10 | Phio Pharmaceuticals Corp. | Topical delivery of nucleic acid compounds |
| JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法 |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
| WO2018213424A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| JP7406793B2 (ja) * | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 |
| EP3647423A4 (en) * | 2017-06-30 | 2021-03-24 | National University Corporation Tokyo Medical and Dental University | DOUBLE STRANDED HETERO-ANTI-MIRNA |
| WO2019014656A1 (en) | 2017-07-14 | 2019-01-17 | Han Si Ping | METALLIC OLIGONUCLEOTIDE JONCTIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS |
| WO2019033079A1 (en) | 2017-08-10 | 2019-02-14 | City Of Hope | CONDITIONAL RNAIDS AND THEIR USES IN THE TREATMENT OF CARDIAC HYPERTROPHY |
| US11298371B2 (en) | 2017-10-11 | 2022-04-12 | Nitto Denko Corporation | Regulation of nucleic acid molecule expression |
| EP3697908A1 (en) | 2017-10-16 | 2020-08-26 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| KR102138495B1 (ko) * | 2017-11-27 | 2020-07-28 | (주)프로스테믹스 | 이중 가닥의 올리고뉴클레오티드 및 그 제조 방법 |
| AU2018378812B2 (en) | 2017-12-06 | 2025-05-22 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| WO2019195765A1 (en) | 2018-04-06 | 2019-10-10 | University Of Massachusetts | Mlk-regulated micrornas in angiogenesis and tumor development |
| JP7580121B2 (ja) * | 2018-08-03 | 2024-11-11 | レモネックス インコーポレイテッド | アトピー性疾患の予防または治療用の薬学的組成物 |
| WO2020033899A1 (en) | 2018-08-10 | 2020-02-13 | University Of Massachusetts | Modified oligonucleotides targeting snps |
| US11279930B2 (en) | 2018-08-23 | 2022-03-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| CN113302298B (zh) | 2018-11-09 | 2025-02-25 | 银杏生物制品公司 | 罗汉果甙的生物合成 |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| WO2020149702A1 (ko) * | 2019-01-18 | 2020-07-23 | 올릭스 주식회사 | Nrl(neural retina leucine zipper)의 발현을 억제하는 비대칭 sirna |
| AU2020268798A1 (en) * | 2019-05-03 | 2021-11-04 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
| KR20220047989A (ko) | 2019-08-09 | 2022-04-19 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| WO2021188390A1 (en) | 2020-03-19 | 2021-09-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| CN116322773A (zh) * | 2020-04-21 | 2023-06-23 | 马萨诸塞大学 | 用于治疗年龄相关性黄斑变性的方法和组合物 |
| WO2021242883A1 (en) | 2020-05-26 | 2021-12-02 | University Of Massachusetts | Synthetic oligonucleotides having regions of block and cluster modifications |
| EP4294449A1 (en) | 2021-02-18 | 2023-12-27 | Oneglobe Holdings Limited | Compositions for conjugating oligonucleotides and carbohydrates |
| US20240352456A1 (en) | 2021-05-13 | 2024-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for treating sickle cell diseases |
| EP4347828A1 (en) | 2021-05-29 | 2024-04-10 | 1Globe Health Institute LLC | Short duplex dna as a novel gene silencing technology and use thereof |
| KR20240014532A (ko) | 2021-05-29 | 2024-02-01 | 1글로브 헬스 인스티튜트 엘엘씨 | 신규한 유전자 침묵 기술로서의 비대칭의 짧은 듀플렉스 dna 및 이의 용도 |
| CN117677699A (zh) | 2021-06-23 | 2024-03-08 | 马萨诸塞大学 | 用于治疗先兆子痫和其他血管生成病症的优化抗flt1寡核苷酸化合物 |
| CN118202046A (zh) * | 2021-07-22 | 2024-06-14 | 中天(上海)生物科技有限公司 | 具有降低的脱靶效应的经修饰的小干扰rna分子 |
| CN118265544A (zh) | 2021-09-16 | 2024-06-28 | 艾维迪提生物科学公司 | 治疗面肩肱型肌营养不良的组合物和方法 |
| WO2023081500A2 (en) * | 2021-11-08 | 2023-05-11 | Dicerna Pharmaceuticals, Inc. | RNAi OLIGONUCLEOTIDE CONJUGATES |
| WO2023207615A1 (zh) * | 2022-04-26 | 2023-11-02 | 南京明德新药研发有限公司 | 一类含由天然核苷酸组成突出端的双链RNAi化合物 |
| CN120091833A (zh) | 2022-08-25 | 2025-06-03 | 南京强新生物医药有限公司 | 缀合寡核苷酸和碳水化合物的新组合物 |
| AU2023390884A1 (en) * | 2022-12-08 | 2025-07-10 | 1Globe Health Institute Llc | Short duplex rna with interspersed deoxyribonucleotides as a gene silencing technology and use thereof |
| WO2025049599A1 (en) | 2023-08-29 | 2025-03-06 | President And Fellows Of Harvard College | Methods for treating muscle-related disorders by modulating prolyl hydroxylase 3 |
| WO2025184876A1 (zh) * | 2024-03-07 | 2025-09-12 | 竣莅医药科技（无锡）有限公司 | 一种rna干扰触发分子与对应核酸干扰药物制剂及其用途 |
| CN118460650B (zh) * | 2024-07-10 | 2025-02-14 | 凯莱英医药集团（天津）股份有限公司 | 一种Nedosiran的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2429814C (en) * | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20070042983A1 (en) * | 2001-05-18 | 2007-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20060211642A1 (en) * | 2001-05-18 | 2006-09-21 | Sirna Therapeutics, Inc. | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
| US7074824B2 (en) | 2001-07-31 | 2006-07-11 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| US6962944B2 (en) | 2001-07-31 | 2005-11-08 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US20040248299A1 (en) * | 2002-12-27 | 2004-12-09 | Sumedha Jayasena | RNA interference |
| WO2005056761A2 (en) | 2003-12-05 | 2005-06-23 | Massachusetts Institute Of Technology | REAGENTS AND METHODS FOR IDENTIFICATION OF RNAi PATHWAY GENES AND CHEMICAL MODULATORS OF RNAi |
| US20060069050A1 (en) * | 2004-02-17 | 2006-03-30 | University Of Massachusetts | Methods and compositions for mediating gene silencing |
| US20050203047A1 (en) * | 2004-03-10 | 2005-09-15 | Ulrich Thomann | Delivery vectors for short interfering RNA, micro-RNA and antisense RNA |
| CA2559955C (en) * | 2004-03-15 | 2016-02-16 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
| US20060142228A1 (en) * | 2004-12-23 | 2006-06-29 | Ambion, Inc. | Methods and compositions concerning siRNA's as mediators of RNA interference |
| EP3889261A1 (en) | 2007-08-27 | 2021-10-06 | 1Globe Health Institute LLC | Compositions of asymmetric interfering rna and uses thereof |
| KR100949791B1 (ko) * | 2007-12-18 | 2010-03-30 | 이동기 | 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도 |
| TW201620525A (zh) | 2014-03-14 | 2016-06-16 | 波士頓生醫公司 | 使ｋ－ｒａｓ靜默之非對稱干擾ｒｎａ組成物及其使用方法 |
-
2008
- 2008-08-27 EP EP21158616.9A patent/EP3889261A1/en active Pending
- 2008-08-27 DK DK08828867.5T patent/DK2193140T3/en active
- 2008-08-27 WO PCT/US2008/074528 patent/WO2009029688A2/en not_active Ceased
- 2008-08-27 EP EP16187862.4A patent/EP3121281B1/en active Active
- 2008-08-27 EP EP08798830A patent/EP2201022A4/en not_active Withdrawn
- 2008-08-27 CN CN200880113323A patent/CN101842381A/zh active Pending
- 2008-08-27 US US12/675,620 patent/US20100286378A1/en not_active Abandoned
- 2008-08-27 CN CN200880113236.9A patent/CN101835789B/zh active Active
- 2008-08-27 JP JP2010523121A patent/JP2010537640A/ja active Pending
- 2008-08-27 EP EP08828867.5A patent/EP2193140B1/en active Active
- 2008-08-27 US US12/199,797 patent/US9328345B2/en active Active
- 2008-08-27 WO PCT/US2008/074531 patent/WO2009029690A1/en not_active Ceased
- 2008-08-27 JP JP2010523120A patent/JP2010537639A/ja active Pending
- 2008-08-27 CN CN201510250692.XA patent/CN105018492B/zh active Active
- 2008-08-27 CA CA2735166A patent/CA2735166C/en active Active
- 2008-08-27 ES ES08828867.5T patent/ES2617877T3/es active Active
- 2008-08-27 CA CA2735167A patent/CA2735167A1/en not_active Abandoned
- 2008-08-27 ES ES16187862T patent/ES2873350T3/es active Active
-
2014
- 2014-02-24 JP JP2014032700A patent/JP5986596B2/ja active Active
-
2015
- 2015-04-20 JP JP2015085681A patent/JP2015130885A/ja active Pending
-
2016
- 2016-03-25 US US15/081,559 patent/US10266821B2/en active Active
- 2016-06-07 JP JP2016113256A patent/JP6236498B2/ja active Active
- 2016-06-21 JP JP2016122512A patent/JP6453275B2/ja active Active
-
2017
- 2017-05-01 JP JP2017091309A patent/JP2017127333A/ja active Pending
-
2019
- 2019-02-20 US US16/280,830 patent/US10927376B2/en active Active
- 2019-03-11 US US16/298,545 patent/US11015195B2/en active Active
-
2021
- 2021-04-22 US US17/237,856 patent/US12344840B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010537640A5 (enExample) | ||
| CA2735167A1 (en) | Composition of asymmetric rna duplex as microrna mimetic or inhibitor | |
| US9068185B2 (en) | Antisense modulation of nuclear hormone receptors | |
| CN112805004A (zh) | 向人脂肪细胞靶向递送治疗剂 | |
| JP2023518409A (ja) | Ａｎｇｐｔｌ３発現を阻害する組成物及び方法 | |
| JP2010537639A5 (enExample) | ||
| IL194419A (en) | Dsrna to inhibit the expression of a 5eg gene in a human cell, a pharmaceutical compound containing it, a vector method | |
| US10933081B2 (en) | Myostatin iRNA compositions and methods of use thereof | |
| US20230340487A1 (en) | Compositions and methods for the treatment of metabolic syndrome | |
| JP7560616B2 (ja) | 膜貫通型セリンプロテアーゼ６（ｔｍｐｒｓｓ６）発現を阻害するための組成物および方法 | |
| CA2591586A1 (en) | Dosage of oligonucleotides | |
| KR20210144601A (ko) | 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물 | |
| US8796238B2 (en) | Short RNA mimetics | |
| KR102301572B1 (ko) | 신규한 핵산 분자 전달용 조성물 및 그 용도 | |
| KR20200014320A (ko) | Apcs의 발현을 억제하는 핵산 | |
| US20200318113A1 (en) | Polynucleotide conjugates and uses thereof | |
| TW202540420A (zh) | 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途 | |
| US20250270549A1 (en) | Msi2 as a therapeutic target for the treatment of myotonic dystrophy | |
| WO2020152869A1 (ja) | 線維症治療剤 | |
| WO2015108162A1 (ja) | β２ＧＰＩの発現を抑制する核酸 | |
| US20250297249A1 (en) | Antisense oligonucleotide complex | |
| CN107466323A (zh) | 酰基‑氨基‑lna和/或烃基‑氨基‑lna寡核苷酸 | |
| KR20260040626A (ko) | 안지오텐시노겐을 표적으로 하는 올리고뉴클레오티드 및 이의 용도 | |
| Chen et al. | Vertex‐Integrated Tetrahedral DNA Nanoframe Enhances miR‐143‐3p Delivery for Osteoarthritis Therapy | |
| WO2025031301A1 (zh) | Fto抑制剂组合物及其应用 |